PTC Therapeutics (NASDAQ:PTCT) Earning Somewhat Positive Press Coverage, Analysis Finds

Media headlines about PTC Therapeutics (NASDAQ:PTCT) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. PTC Therapeutics earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.2710430149446 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Several research analysts recently commented on the company. Barclays reissued a “hold” rating on shares of PTC Therapeutics in a research note on Tuesday, January 23rd. Credit Suisse Group reaffirmed a “buy” rating and issued a $28.00 target price on shares of PTC Therapeutics in a research note on Tuesday, January 30th. JPMorgan Chase & Co. raised their target price on PTC Therapeutics to $15.00 and gave the stock a “neutral” rating in a research note on Friday, November 24th. Bank of America downgraded PTC Therapeutics from a “neutral” rating to an “underperform” rating in a research note on Thursday, October 26th. Finally, Zacks Investment Research downgraded PTC Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, January 13th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $19.57.

Shares of PTC Therapeutics (NASDAQ PTCT) traded down $0.58 during trading on Friday, reaching $23.93. The company had a trading volume of 577,941 shares, compared to its average volume of 956,830. PTC Therapeutics has a 12 month low of $8.12 and a 12 month high of $28.75. The stock has a market cap of $992.86, a PE ratio of -8.28 and a beta of 1.73. The company has a quick ratio of 2.97, a current ratio of 3.08 and a debt-to-equity ratio of 0.98.

In other news, CEO Stuart Walter Peltz sold 2,230 shares of PTC Therapeutics stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $18.03, for a total value of $40,206.90. Following the completion of the transaction, the chief executive officer now owns 26,646 shares in the company, valued at approximately $480,427.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 2,719 shares of company stock valued at $48,848 over the last 90 days. 8.10% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: “PTC Therapeutics (NASDAQ:PTCT) Earning Somewhat Positive Press Coverage, Analysis Finds” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.

Insider Buying and Selling by Quarter for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply